RaySearch Laboratories AB (publ) (LON:0GRZ)
United Kingdom · Delayed Price · Currency is GBP · Price in SEK | Market Cap | 438.29M -37.4% |
| Revenue (ttm) | 100.53M +3.2% |
| Net Income | 15.45M -6.6% |
| EPS | 0.46 -5.8% |
| Shares Out | n/a |
| PE Ratio | 28.79 |
| Forward PE | 23.68 |
| Dividend | 0.32 (2.44%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 3,876 |
| Open | 171.60 |
| Previous Close | 172.20 |
| Day's Range | 171.60 - 173.70 |
| 52-Week Range | 161.00 - 258.00 |
| Beta | 0.82 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 3, 2026 |
About RaySearch Laboratories AB
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer treatment worldwide. It offers RayStation, a treatment planning system for cancer centers; RayCare, an oncology information system for clinics; RayIntelligence, cloud-based oncology analytics system that cancer centers can use to gather, structure and analyze data; and RayCommand, a treatment control system designed to link the treatment machine and the treatment planning and oncology information systems. It also provides µ-RayStation* (Micro-... [Read more]
Financial Performance
In 2025, RaySearch Laboratories AB's revenue was 1.34 billion, an increase of 12.78% compared to the previous year's 1.19 billion. Earnings were 227.80 million, an increase of 11.94%.
Financial numbers in SEK Financial StatementsNews
RaySearch Laboratories AB Earnings Call Transcript: Q3 2026
Q3 sales hit a record SEK 394 million, with 18% organic growth, but temporary hardware volumes pressured margins. Strong order intake and pipeline underpin confidence in the FY margin target of at least 25%, though Q4 must be exceptionally strong.
RaySearch Laboratories AB Quarterly report: Q3 2026
RaySearch Laboratories AB has published its Q3 2026 quarterly earnings report on November 3, 2026.
RaySearch Laboratories AB Slides: Q3 2026
RaySearch Laboratories AB has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
RaySearch Laboratories AB Earnings Call Transcript: Q2 2026
Q2 2026 saw an 11% drop in net sales due to U.S. deal delays, but order intake rose 23% and recurring revenue provided stability. Management expects to recover postponed orders in Q3 and maintains a strong outlook for H2, aiming for a 25% EBIT margin for 2026.
RaySearch Laboratories AB Quarterly report: Q2 2026
RaySearch Laboratories AB has published its Q2 2026 quarterly earnings report on August 13, 2026.
RaySearch Laboratories AB Slides: Q2 2026
RaySearch Laboratories AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
RaySearch Laboratories AB Earnings Call Transcript: Q1 2026
Q1 2026 saw a 20% sales decline due to currency and timing of large deals, but profitability stayed strong with a 23% margin. Recurring revenue and order backlog remain robust, and momentum in RayCare and proton therapy segments supports a positive outlook.
RaySearch Laboratories AB Quarterly report: Q1 2026
RaySearch Laboratories AB has published its Q1 2026 quarterly earnings report on April 29, 2026.
RaySearch Laboratories AB Slides: Q1 2026
RaySearch Laboratories AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 29, 2026.
RaySearch Laboratories AB Earnings Call Transcript: Q4 2025
Record net sales and profitability were achieved in 2025, driven by strong license and recurring revenues, major clinical milestones, and robust global demand. The company is confident in reaching a 25% EBIT margin in 2026 and has raised its dividend proposal, with new financial targets to be set during the year.
RaySearch Laboratories AB Quarterly report: Q4 2025
RaySearch Laboratories AB has published its Q4 2025 quarterly earnings report on February 12, 2026.
RaySearch Laboratories AB Slides: Q4 2025
RaySearch Laboratories AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 12, 2026.
RaySearch Laboratories AB Annual report: Q4 2025
RaySearch Laboratories AB has published its Q4 2025 annual report on February 12, 2026.
RaySearch Laboratories AB Earnings Call Transcript: Q3 2025
Record Q3 net sales and EBIT margin driven by strong license and support revenue growth, major customer wins, and robust demand for oncology software. Order intake rose 17%, with Pinnacle system replacements accelerating and RayCare interest intensifying.
RaySearch Laboratories AB Quarterly report: Q3 2025
RaySearch Laboratories AB has published its Q3 2025 quarterly earnings report on November 7, 2025.
RaySearch Laboratories AB Slides: Q3 2025
RaySearch Laboratories AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 7, 2025.
RaySearch Laboratories AB Earnings Call Transcript: Q2 2025
Q2 2025 saw a 4% sales decline due to delayed orders and tough year-over-year comparisons, but strong July order intake and a robust backlog support continued growth expectations. Operating margin was 12% (17% adjusted), and management maintains a 25% margin target by 2026.
RaySearch Laboratories AB Quarterly report: Q2 2025
RaySearch Laboratories AB has published its Q2 2025 quarterly earnings report on August 8, 2025.
RaySearch Laboratories: Interim report April - June 2025
STOCKHOLM , Aug. 8, 2025 /PRNewswire/ -- SECOND QUARTER (APRIL - JUNE 2025) Order intake amounted to SEK 241.2 M (290.3) Net sales amounted to SEK 304.9 (318.9) Operating profit amounted to SEK 36.4 M...
Invitation to presentation of RaySearch's interim report for the second quarter of 2025
STOCKHOLM , July 18, 2025 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the second quarter of 2025, on August 8, 2025, at 10.00 am ...
RaySearch Laboratories AB Earnings Call Transcript: Q1 2025
Record Q1 sales and order intake drove a 29% revenue increase and a 23% operating margin, with strong license and support growth. Major orders, new product launches, and robust cash flow support a positive outlook and margin target of 25% by 2026.
RaySearch Laboratories AB Quarterly report: Q1 2025
RaySearch Laboratories AB has published its Q1 2025 quarterly earnings report on May 9, 2025.
Interim report January 1 - March 31, 2025: RaySearch Laboratories
STOCKHOLM , May 9, 2025 /PRNewswire/ -- FIRST QUARTER (JANUARY - MARCH 2025) Order intake amounted to SEK 409.6 M (238.5) Net sales amounted to SEK 331.7 M (257.2) Operating profit amounted to SEK 74...
RaySearch Laboratories and Vision RT present innovations in surface guided treatment planning at ESTRO
STOCKHOLM , May 3, 2025 /PRNewswire/ -- At this week's ESTRO conference in Vienna, RaySearch Laboratories AB (publ) and Vision RT proudly announces the next step in their collaboration: the full integ...
Invitation to presentation of RaySearch's interim report for the first quarter of 2025
STOCKHOLM , April 25, 2025 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the first quarter of 2025, on May 9, 2025, at 10.00 am CES...